{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:52:50Z","timestamp":1791006770120,"version":"4.1.0"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.5551\/jat.66098","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:09:58Z","timestamp":1779487798000},"page":"1272-1284","source":"Crossref","is-referenced-by-count":0,"title":["Liver Dysfunction Assessed by Albumin \u2013 Bilirubin (ALBI) Score is Associated with Disturbed Cholesterol Profiles and Reduced Survival in Patients with Chronic Limb-Threatening Ischemia"],"prefix":"10.5551","volume":"33","author":[{"given":"Kentaro","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University"},{"name":"Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University"},{"name":"Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Furuyama","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Onohara","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, National Hospital Organization Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023; 78: 1966-1986","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023; 77: 1335-1347","DOI":"10.1097\/HEP.0000000000000004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol, 2018; 68: 335-352","DOI":"10.1016\/j.jhep.2017.09.021"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) W\u00f3jcik-Cichy K, Ko\u015bli\u0144ska-Berkan E, Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol, 2018; 4: 1-6","DOI":"10.5114\/ceh.2018.73155"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep, 2021; 11: 15938","DOI":"10.1038\/s41598-021-95581-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ogawa T, Sato T, Tanaka M, Akiyama Y, Nakata K, Kouzu H, Mori K, Aida H, Kawaharata W, Hosaka I, Suzuki T. Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for the development of ischemic heart disease: a 10-year cohort study. Circ Rep, 2025; 7: 350-358","DOI":"10.1253\/circrep.CR-25-0019"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O\u2019Beirne J, Fox R, Skowronska A, Palmer D, Yeo W. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J Clin Oncol, 2015; 33: 550-558","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999-2008. Front Cardiovasc Med, 2023; 10: 1172178","DOI":"10.3389\/fcvm.2023.1172178"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tan SH, Zhou XL. Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation. Clinics (Sao Paulo), 2023; 78: 100301","DOI":"10.1016\/j.clinsp.2023.100301"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Barbosa JV, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, Lai M. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol, 2022; 117: 453-461","DOI":"10.14309\/ajg.0000000000001606"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kj\u00e6r MS, Mangla KK, Tarp JM, Khunti K. Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur, 2024; 36: 100780","DOI":"10.1016\/j.lanepe.2023.100780"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bj\u00f6rnson E, Samaras D, Adiels M, Kullberg J, B\u00e4ckhed F, Bergstr\u00f6m G, Gummesson A. Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification. Sci Rep, 2023; 13: 13217","DOI":"10.1038\/s41598-023-39390-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fadaei R, Poustchi H, Meshkani R, Moradi N, Golmohammadi T, Merat S. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep, 2018; 8: 11691","DOI":"10.1038\/s41598-018-29639-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kleemann R, Verschuren L, Van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol, 2007; 8: R200","DOI":"10.1186\/gb-2007-8-9-r200"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin\u2010Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest. Hepatology, 2007; 46: 32-36","DOI":"10.1002\/hep.21669"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Dobi\u00e1sov\u00e1 M, Frohlich J. The plasma parameter log(TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem, 2001; 34: 583-588","DOI":"10.1016\/S0009-9120(01)00263-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Despr\u00e9s JP. Total cholesterol\/HDL cholesterol ratio vs LDL cholesterol\/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec cardiovascular study. Arch Intern Med, 2001; 161: 2685-2692","DOI":"10.1001\/archinte.161.22.2685"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sun T, Chen M, Shen H, PingYin, Fan L, Chen X, Wu J, Xu Z, Zhang J. Predictive value of LDL\/HDL ratio in coronary atherosclerotic heart disease. BMC Cardiovasc Disord, 2022; 22: 273","DOI":"10.1186\/s12872-022-02706-6"},{"key":"19","unstructured":"19) De Ul\u00edbarri JI, Gonz\u00e1lez-Madro\u00f1o A, de Villar NG, Gonz\u00e1lez P, Gonz\u00e1lez B, Mancha A, Rodr\u00edguez F, Fern\u00e1ndez G. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp, 2005; 20: 38-45"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Matyas C, Hask\u00f3 G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol, 2021; 18: 117-135","DOI":"10.1038\/s41569-020-0433-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol, 2003; 23: 1881-1888","DOI":"10.1161\/01.ATV.0000091338.93223.E8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dobi\u00e1sov\u00e1 M, Frohlich J, Sedov\u00e1 M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res, 2011; 52: 566-571","DOI":"10.1194\/jlr.P011668"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020; 69: 1691-1705","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) O. Rafikova, R. Rafikov, & E. Nudler. Catalysis of S-nitrosothiols formation by serum albumin: The mechanism and implication in vascular control. Proc. Natl. Acad. Sci. U.S.A., 2002; 99: 5913-5918","DOI":"10.1073\/pnas.092048999"},{"key":"25","unstructured":"25) Al-Mallah MH, Hatahet H, Cavalcante JL, Khanal S. Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non-ST segment elevation myocardial infarction. Cardiol J, 2009; 16: 227-233"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cho KH, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Seung KB. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). Am J Cardiol, 2010; 106: 1061-1068","DOI":"10.1016\/j.amjcard.2010.06.009"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Reddy VS, Bui QT, Jacobs JR, Begelman SM, Miller DP, French WJ. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol, 2015; 115: 557-562","DOI":"10.1016\/j.amjcard.2014.12.006"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Wang B, Liu J, Chen S, Ying M, Chen G, Liu L, Lun Z, Li H, Huang H, Li Q, Yu Y. Malnutrition affects cholesterol paradox in coronary artery disease: a 41,229 Chinese cohort study. Lipids Health Dis, 2021; 20: 36","DOI":"10.1186\/s12944-021-01460-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Wang TY, Newby LK, Chen AY, Mulgund J, Roe MT, Sonel AF, Bhatt DL, DeLong ER, Ohman EM, Gibler WB, Peterson ED. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clin Cardiol, 2009; 32: E22-8","DOI":"10.1002\/clc.20518"},{"key":"30","unstructured":"30) Feingold KR, Grunfeld C. Effect of inflammation and infection on lipids and lipoproteins. In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u2013. Updated 2025 Jun 18. PMID: 26561701"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol, 2016; 22: 6201-6213","DOI":"10.3748\/wjg.v22.i27.6201"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Pose E, Trebicka J, Mookerjee RP, Angeli P, Gin\u00e8s P. Statins: old drugs as new therapy for liver diseases? J Hepatol, 2019; 70: 194-202","DOI":"10.1016\/j.jhep.2018.07.019"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Vargas JI, Arrese M, Shah VH, Arab JP. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep, 2017; 19: 43","DOI":"10.1007\/s11894-017-0584-7"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/10\/33_66098\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:02:32Z","timestamp":1791003752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/10\/33_66098\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66098","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"66098"}}